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INTRODUCTION 
 
RENAL DISEASES 8 
 
Renal diseases are as complex as its structure, but there is facilitated by 
dividing them into those that affect the four basic morphologic components: - 
glomeruli, tubules, interstitium and blood vessels. Some components appear to be 
more vulnerable to specific forms of renal injury; eg:-most glomerular diseases are 
immunologically mediated, whereas tubular and interstitial disorders are frequently 
caused by toxic (or) infectious agents. In addition the anatomic and functional 
interdependence of the components of the kidney implies that damage to one almost 
always secondarily affects the others. 
 
Severe glomerular damage impairs the flow through the peritubular vascular 
system and also delivers potentially toxic products to tubules – tubular destruction by 
increasing intraglomerular pressure may induce glomerular atrophy. However, there is 
a tendency for all forms of chronic renal diseases ultimately to destroy all four 
components of the kidney, culminating in chronic renal failure and what has been 
called End Stage Renal Disease. 
 
Renal diseases are responsible for a great deal of morbidity. Approximately 
70,000 deaths are attributed yearly to renal diseases in united states. Millons of people 
are affected annually by non- fatal kidney diseases, most notably infections of the 
kidney or lower urinary tract, kidney stones and urinary obstruction. Similarly dialysis 
and transplantation keep many patients alive who would formerly have died of renal 
failure. Adding to the pool of renal morbidity. 
 
Clinical manifestations of renal diseases:- 8 
The clinical manifestations of renal diseases can be grouped into reasonably 
well-defined syndromes.  
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Azotemia is a biochemical abnormality that refers to an elevation of the BUN and 
creatinine levels and is related largely to a decreased GFR. Azotemia is produced by 
many renal disorders, but it also arises from extra-renal disorders. 
 
Pre-renal azotemia is encountered when there is hypoperfusion of the kidneys 
( eg: in hemorrhage, shock, volume depletion, CRF) that impairs renal function in the 
absence of parenchymal damage. 
 
Similarly post-renal azotemia is seen whenever urine flow is obstructed below 
the level of the kidney. Relief of the obstruction is followed by correction of the 
azotemia. 
 
When azotemia becomes associated with a constellation of clinical signs and 
symptoms and biochemical abnormalities, it is termed uremia. Uremia is 
characterized not only by failure of renal excretory function, but also by a host of 
metabolic and endocrine alterations, secondary involvement of the gastro-intestinal 
system ( eg: uremic gastroenteritis) , peripheral nerves (eg: peripheral neuropathy) 
and heart (eg: uremic fibrinous pericarditis) , which is usually necessary for the 
diagnosis of uremia. 
 
The clinical presentations of renal disease include:- 
 
Acute Nephritic Syndrome is a glomerular syndrome dominated by the acute onset 
of usually grossly visible hematuria, mild to moderate proteinuria and hypertension – 
classic presentation of acute post streptococcal glomerulonephritis. 
 
Nephrotic Syndrome is characterized by heavy proteinuria (more than 3.5gm/day), 
hypoalbuminemia, severe edema, hyperlipidemia and lipiduria. 
 
Asymptomatic hematuria (or) Proteinuria (or) a combination of both is usually a 
manifestation of subtle (or) mild glomerular abnormalities. 
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Acute Renal Failure is dominated by oliguria (or) anuria, with recent onset of 
azotemia. It can result from glomerular , interstitial (or) vascular injury (or) acute 
tubular necrosis. 
 
Chronic Renal Failure is characterized by prolonged symptoms and signs of uremia, 
is the end result of all chronic renal parenchymal diseases. 
 
Renal Tubular Defects are dominated by polyuria, nocturia and electrolyte disorders 
(eg: metabolic acidosis). They are the result of either diseases that directly affect 
tubular structure (eg: medullary cystic diseases) or defects in specific tubular 
functions. The latter can be inherited (eg: familial nephrogenic diabetes, cystinuria, 
renal tubular acidosis) or acquired ( eg: lead nephropathy). 
 
Urinary Tract Infection is characterized by bacteriuria and pyuria. The infection 
may be symptomatic (or) asymptomatic and it may affect the kidney (pyelonephritis) 
or the bladder (cystitis) only.   
 
Nephrolithiasis (renal stones) is manifested by renal colic, hematuria and recurrent 
stone formation. 
 
Urinary Tract Obstruction and renal tumors represent specific anatomic lesions 
with often varied clinical manifestations. 
 
Warning signs of Kidney diseases 2 
 
Kidney disease usually affects both the kidneys. If the kidneys ability to filter 
the blood is seriously damaged by disease, wastes and excess fluid may build up in 
the body. 
Six warning signs of kidney disease include:- 
            High blood pressure 
• Blood and / or protein in the urine 
• A creatinine and BUN test, outside the normal range 
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       Bun and creatinine are waste that builds up in blood when the kidney function 
is reduced. 
• A GFR less than 60 
• More frequent urinaton, particularly at night, difficult or painful urination. 
• Puffiness around eyes, swelling of hand and feet. 
 
 
 DRUGS INDUCED KIDNEY DISEASES 
Drug induced kidney diseases are the major adverse event associated with 
multiple medication classes. Medications use accounts for 2% of hospital admissions 
for acute renal failure and upto 15% of admissions into intensive care.  
 
Hospital-acquired renal failure includes any documented incident of renal 
failure that occurs within the hospital setting. Hospitalized patients are vulnerable to 
renal failure from a variety of causes, including diagnostic procedures (1V contrast), 
sudden decrease in blood pressure (gastrointestinal bleed, sepsis, variceal bleed) and 
the addition of nephrotoxic medications (aminoglycosides, amphotericin, 
chemotherapy). Upto 16% of patients with baseline normal renal function who 
experience renal injury within the hospital setting have medication-induced renal 
failure. 
 
Patients who experience acute-onset renal failure often complain of increased 
shortness of breath, ankle swelling and weight gain. These symptoms reflect the 
reduced ability of the kidney to clear extra fluid from the body. If the kidney failure is 
due to a medication, stopping the medication may allow the kidney to recover .If the 
kidney has extensive damage; the kidney may reduce or even stop producing urine. 
Hemodialysis may be necessary for a short-term bridge until the kidney can recover. 
In some cases, the damage is irreversible and the patient will require life-long dialysis 
or a kidney transplant. 
 
Drug-induced renal disease can mimic renal disease from other causes, such as 
autoimmune disease and infection. A thorough physical examination and medical 
history should be performed. Laboratory tests will show an increase in serum 
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creatinine and blood urea nitrogen (BUN) when a significant loss of kidney function 
occurs. Additional urine tests, such as protein excretion, creatinine concentration, 
osmolality, or sodium excretion may be requested to pinpoint the cause of the renal 
defect. Finally, in some cases, a renal biopsy may be performed to directly examine 
he histological changes within the kidney. 
 
Renal failure, whether caused by medications or other processes, can be classified as 
acute or chronic. Chronic renal failure develops over a long-period of time (many 
months to years) with continued exposure to a nephrotoxin or from the natural ageing 
process or onset of disease. Chronic renal failure can be further classified into five 
stages of progressively worsening renal function. A subset of all chronic renal failure 
patients will eventually progress to stage 5(end-stage renal disease). Most patients 
who reach stage 5 renal failure require dialysis or a renal transplant to live. 
 
PRE-RENAL INJURY 11 
Pre-renal causes result in decreased blood flow to the kidney resulting in acute 
renal failure. Patients with congestive heart failure have reduced ability to effectively 
pump blood to other organs. An exacerbation (worsening) of heart failure may 
increase the risk of acute renal failure by reducing blood flow into the kidneys. 
Excessive dehydration due to fluid loss (protracted vomiting, diarrhoea , blood loss, 
etc.) without fluid replacement will cause acute renal failure. Severe infections can 
lead to sepsis, a life-threatening condition that results in a drop in blood pressure 
significant enough to reduce blood flow into the kidneys. Excessive diuretic use may 
lead to severe dehydration and increase the risk of acute renal failure. 
 
The kidney tries to compensate for decreased renal blood flow by altering the 
hemodynamics (blood flow) within the kidney, but these changes may not be 
sufficient to prevent acute renal failure. If the loss of blood flow to the kidney is 
prolonged, the direct damage to kidney tissue may occur due to loss of adequate 
perfusion and oxygenation of kidney tissue. 
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Blood and Urine studies to distinguish pre-renal from intra- renal injury 11 
 
                                                      
Table - 1 
 
  The fractional excretion of sodium is equal to 100 [3 (urine sodium/ serum 
sodium)] [4 (urine creatinine/ serum creatinine)]. This value is less than 1% in most 
patients with pre-renal injury. 
 
 In patients with pre – renal injury, the parenchyma is undamaged and the 
kidneys respond as if volume depletion has occurred. Thus, kidneys avidly reabsorb 
sodium in order to reabsorb water. Specific causes of fractional excretion of sodium 
less than 1% that are not the result of pre – renal injury include contrast nephropathy 
and pigment nephropathy. 
                                     
  INTRA-RENAL INJURY 
Intra-renal failure sometimes called intrinsic kidney damage is due to direct 
insult to kidney tissues, especially the nephron. It is subdivided into four categories: 
 
• Tubular disease 
• Glomerular disease 
• Vascular disease 
•  In intrinsic injury, the renal parenchyma is injured. The damage to tubule 
cells leads to certain urine microscopic studies. Parenchymal injury causes 
impaired sodium reabsorption and results in a fractional excretion of sodium 
greater than 3 % and an isotonic urine osmolality of 250- 300 m OSm. 
 
 
 
 
BUN to 
creatinine ratio 
Urine osmolality Fractional 
excretion of 
sodium 
Pre-renal injury >20 :1 >500 m OSm <1% 
Intra- renal injury <20 :1 250 – 300 m OSm >3% 
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Tubular disease 
Acute tubular necrosis is the most common cause of intra-renal toxicity in 
hospitalized patients. This condition is usually induced by ischemia (or) toxins. In 
ischemic acute tubular necrosis, unlike pre-renal injury, the GFR does not improve 
with the restoration of renal blood flow. Ischemic acute tubular necrosis is frequently 
reversible, but if the ischemia is severe enough to cause cortical neurosis, irreversible 
renal failure can occur. 
 
Contrast agents and aminoglycosides are the agents most often associated with 
acute tubular necrosis. The condition can also be caused by pigment from 
myoglobiuria (rhabdomyolysis ), hemoglobinuria (hemolysis ). 
 
Acute tubular necrosis has 3 phases. Renal injury evolves during the initiation 
phase, which lasts for hours to days. In the maintenance phase, which last for days to 
weeks, the GFR reaches its maximum and urine output is at its lowest. The recovery 
phase lasts for days, often beginning with post acute tubular necrosis diuresis. 
Hypovolemia from excess urine output is a concern during this phase. Despite 
recovery of urine production, patients can still have difficulty with uremia and 
homeostasis of electrolytes and acid because of tubular function is not completely 
recovered. Diligent monitoring is indicated throughout all phases of acute tubular 
necrosis. 
 
Patients at risk for acute tubular necrosis include those diabetes, congestive 
heart failure (or) chronic renal insufficiency. Acute tubular necrosis may be prevented 
by promptly treating patients with reversible causes of ischemia (or) pre-renal injury 
and by maintaining appropriate hydration in patients who are receiving nephrotoxins. 
 
Glomerular Disease               
Glomerulonephritis is characterized by hypertension, proteinuria and 
hematuria. Most of glomerulonephritis are associated with chronic renal disease. In 
general two types of glomerulonephritis that cause pre renal injury are rapidly 
progressive glomerulonephritis and acute proliferative glomerulonephritis .The later 
type occurs in patients with bacterial endocarditis (or) other post infections 
conditions. 
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Rapidly progressive glomerulonephritis can be a primary disorder, or it can 
occur secondary to systematic disease.  Once this condition is suspected, treatable 
systematic disease must be sought through serologic markers or renal biopsy. Renal 
function can decline quickly in patients with rapidly progressive glomerulonephritis, 
end stage renal disease can develop in days to weeks. Patients with rapidly 
progressive glomerulonephritis are treated with gluco corticoids and 
cyclophosphamide (cytoxan) . 
  
Vascular Disease 
 
Microvascular (or) macrovascular disease (major renal artery occlusion) (or) 
severe abdominal aortic disease) can cause renal failure. 
The classic microvascular disease often present with microangiopathic hemolysis and  
renal failure occurring because of capillary thrombosis (or) occlusion, often with 
accompanying thrombocytopenia. Typical examples of these diseases are :  
 
• Thrombotic thrombocytopenic purpura 
• Hemolytic uremic syndrome 
• HELLP syndrome ( hemolysis, elevated liver enzymes ) 
 
The classic pentad in thrombotic thrombocytopenic purpura includes; 
• Fever 
• Neurologic changes 
• Renal failure 
• Microangiopathic hemolytic anemia 
• Thrombocytopenia 
 
Hemolytic uremic syndrome is similar to thrombotic thrombocytopenic 
purpura but does not present with neurologic changes. 
 
HELLP syndrome is a type of hemolytic uremic syndrome that occurs in 
pregnant woman with the addition of transaminase elevations. 
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The microvascular diseases that cause renal failure are often treated with 
plasmapheresis and sometimes with cortico-steroids. An increasing platelet count is a 
marker of improvement Atheroembolic disease is another important cause of 
irreversible acute renal failure. Patients with atherosclerotic disease who undergoes an 
invasive procedure (eg: vascular surgery (or) interventional vascular studies (or) have 
an acute arrhythmia are at increased risk for renal failure induced by atheroembolic. 
Acute renal failure from embolic disease may present one day to seven weeks after 
the inciting event. 
 
Atheroembolism is relatively common in tertiary care and intensive care units, 
presenting classically with “purple toes and renal failure”.. The diagnosis of 
atheroembolic disease can be confirmed on skin (or) renal biopsy. Treatment is 
nonspecific, but avoiding further vascular intervention and anticoagulation is strongly 
recommended. 
 
Interstitial Disease 
 
Acute interstitial nephritis usually presents with fever, rash and esinophilia. 
Urine staining that is positive for eosinophils is suggestive of this condition. Acute 
interstitial nephritis is usually the result of an allergic reaction to a drug, but it may 
also be caused by autoimmune disease, infection (or) infiltrative disease. 
 
Many drugs can cause interstitial nephritis, but the most common are; 
• NSAIDS 
• Penicillins 
• Cephalosporins 
• Sulfonamides 
• Diuretics 
• Allopurinol 
 
Renal function should improve after the offending agent is withdrawn. 
Corticosteroids are sometimes helpful in speeding recovery. 
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                  Common medications associated with intra – renal injury 4 
  
    Pathoetiology 
 
  Medications   Clinical 
findings 
     Treatment 
Intrinsic renal 
injury  
(vascular effects, 
Thrombotic 
microangiopathy) 
Ciclosporin ,tacrolimus, 
mitomycinC, quinine, 
5-flurouracil, 
ticlopidine,clopidogrel, 
gemcitabine, bleomycin.   
 
Fever 
Microangiopathic 
Haemolytic 
anaemia 
thrombocytopenia 
Discontinue 
medication 
Supportive care 
Plasmapherisis  
if indicated 
Intrinsic renal 
injury 
(vascular effects, 
cholesterol 
emboli) 
Heparin, warfarin, 
Streptokinase 
Fever 
Microangiopathic 
Haemolytic 
anaemia 
thrombocytopenia 
Discontinue 
medication 
Supportive care 
Plasmapherisis 
if indicated 
 
Intrinsic 
renal injury 
(tubular toxicity) 
Aminoglycosides, radio 
contrast media, 
Cisplatin, nedaplatin 
Methoxyflurane 
Amphotericin B 
Cephaloridine 
Streptozocin, 
Tacrolimus, carbamazepine, 
quionolones, cidofovir, 
mannitol, foscarnet 
 
FeNa>2%, 
UoSm<350,  
urinary sediment 
with granular 
casts, tubular 
epithelial cells 
Drug 
discontinuation 
Supportive care 
Intrinsic renal 
injury 
(rhabdomyolysis) 
Lovastatin, ethanol, codeine, 
barbiturates, diazepam 
Elevated CPK, 
acute tubular 
necrosis,  
Urine sediment 
 
Drug 
discontinuation 
Supportive care 
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                                                               Table - 2 
 
POST-RENAL INJURY 11 
   Post- renal injury can only occur if both urinary outflow tracts are obstructed 
(or) the outflow tract of a solitary kidney is obstructed. The condition is most often 
due to obstruction of the lower urinary tract. 
 
Intrinsic renal 
injury  
(severe 
haemolysis) 
Quinine, quinindine, 
sulfonamides, hydralazine, 
triamterene, nitrofurantoin, 
mephenytoin 
 
High LDH, 
Decreased 
haemoglobin 
Drug 
discontinuation  
Supportive care 
Intrinsic renal 
injury  
(immune –
mediated 
interstitial 
inflammation) 
Penicillin, methicillin, 
ampicillin, rifampicin, 
sulfonamides, thiazides, 
cimetidine, phenytoin, 
cephalosporines, furosemide, 
ciprofloxacin, clarithromycin, 
pantoprazole, omeprazole, 
NSAIDS. 
 
Fever, rash, 
eosinophilia,  
Urine sediment 
showing pyuria, 
white cell cast 
eosinophiluria. 
Drug 
discontinuation,  
Supportive care 
Intrinsic renal 
injury  
(glomerulopathy) 
Gold, penicillamine, 
Captopril, NSAIDS, 
Lithium, fenoprofen, mercury, 
mefenamate, 
Interferon-alfa, foscarnet 
 
Edema, moderate 
– servere 
proteinuria, RBC 
casts possible 
Drug 
discontinuation, 
Supportive care 
Intra-renal 
tubular 
obstruction 
Aciclovir, methotrexate, 
sulphanilamide, 
triamterene,foscarnet,indinavir,  
Benign urine 
sediment with 
obstruction, 
Acute tubular 
necrosis 
Drug 
discontinuation, 
Supportive care 
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Patients with severe oliguria (or) anuria ( output less than 100ml of urine  per 
day) are likely to have post – renal injury. However not all patients with post- renal 
injury are oliguric. It usually results from a mechanical barrier to moving urine from 
the collecting tubules into the bladder and through the ureters. Mechanical obstruction 
may be caused by enlargement of the prostate, kidney stones or drugs that precipitate 
in the kidney. (Acyclovir, ganciclovir). 
 
The primary causes of post – renal injury include;  
• Prostatic hypertrophy 
• Prostatic cancer 
• Cervical cancer 
• Retroperitoneal diseases 
    
Intratubular causes include, 
                  Crystals (eg: urates) 
                   Myeloma light chains 
 
One of the first elevation steps in most patients with renal injury is to 
determine whether a patient has post –renal failure, because treatment is frequently 
relatively easy and the potential for recovery of renal function is often inversely 
related to the duration of obstruction. Bladder catheterization may be diagnostic and 
therapeutic inpatients with bladder (or) urethral obstruction. 
 
Hydronephrosis detected on renal ultrasound examination is the major signal 
that obstruction is present. 
In patients with post–renal injury, treatment efforts are directed at the underlying 
disease. Treatments are available for underlying disease include;  
• Bladder caterterization 
• Percutaneous nephrostomy 
• Lithotripsy 
• Ureteral stenting 
• Urethral stenting   
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Causes of acute renal injury 9 
    Classification Common Clinical Disorders 
Pre- renal injury 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Functional injury 
 
 
 
 
 
Intravascular volume depletion 
Hemorrhage (surgery, trauma) 
Dehydration (gastrointestinal losses, aggressive diuretic administration) 
Severe burns, Hypovolemic shock 
Sequestration (peritonitis, pancreatitis) 
Decreased effective circulating volume 
Cirrhosis with ascites 
Congestive heart failure 
Hypotension, shock syndromes 
Antihypertensive vasodilating medications 
Septic shock, Cardiomyopathy 
 
Increased renal vascular occlusion/ constriction 
Bilateral renal artery stenosis 
Unilateral renal stenosis in solitary kidney 
Renal artery (or) vein thrombosis (embolism, atherosclerosis) 
Vasopressor medications  
 
Afferent arteriole vasoconstrictors 
Cyclosporine, NSAIDS 
Efferent arteriole vasodilators 
ACEI’s 
Angiotensin receptor -2 antagonists 
 
Glomerular disorders 
Glomerulonephritis 
SLE (Systemic Lupus Erythematous) 
Malignant hypertension, Vasculitic disorder 
Acute tubular necrosis 
Prolonged pre-renal states 
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Intrinsic renal injury 
 
 
 
Post –renal injury 
 
Drug induced (contrast media, aminoglycosides, amphotericin B) 
Acute interstitial nephritis 
Drug induced (quinolones, penicillins sulpha drugs) 
 
Ureter obstruction 
[Bilateral (or) unilateral in solitary kidneys] 
Malignancy (prostate (or) cervical cancer) 
Prostate hypertrophy, Renal calculi 
 
                                                              Table-3 
CHRONIC RENAL INJURY 4 
Prolonged exposure of the kidney to analgesics, calcineurin inhibitors or 
lithium can cause chronic renal damage. Chronic high doses (2-3gm/ day) of 
phenacetin, acetaminophen, aspirin and NSAIDS are at increased risk of developing 
end stage renal disease. Chronic use of these drugs can cause patchy necrosis and 
fibrosis of the renal medullary interstitium with occasional mononuclear cell 
infiltration, and atrophy of henle’s loop. Inhibition of vasodilatory prostaglandins by 
NSAIDS and salicyclates can induce medullary ischemia. Drug metabolites tend to 
become concentrated within the medullary   gradient; high levels at the papillary tip 
and generated via lipid peroxidation induce tissue damage. 
 
Staging of chronic renal injury based on GFR 9 
                                                           Table-4 
 
 
Stage 
 
Description 
 
GFR 
     1 
 
    2 
 
    3  
    4 
    5 
At increased risk 
 
Kidney damage with normal or increased 
GFR 
Kidney damage with mild decreased GFR 
Moderate decreased GFR 
Severe decreased GFR 
Kidney failure 
>90(with CKD risk factors) 
>90 
60-89  
 
30-59 
15-29 
<15(need for renal 
transplant therapy) 
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Chronic fibrosis leads to small kidneys in most patients who present with 
concentrating defects, sterile pyuria or mild proteinuria; 25 – 50% of patients presents 
with papillary sloughing which can be accompanied by haematuria and flank pain. 
Urogenital transitional carcinomas and renal cell cancers have also been linked with 
prolonged analgesic use. 
 
Chronic fibrosis with an obliterative arteriolopathy and tubular collapse gives 
rise to a classic biopsy pattern of striped interstitial fibrosis in patients receiving long 
– term treatment with calcineurin inhibitors.  
 
Chronic use of lithium for bipolar disorders or depression can cause interstitial 
fibrosis and nephrogenic diabetes insipidus. Examination of renal biopsies reveals 
prevalent cortical and medullary tubular cysts or dilatations (primarily of distal and 
collecting tubules), both focal segmental glomerulosclerosis and global sclerosis, and 
chronic tubulointerstitial nephropathy. 
 
ELECTROLYTE AND ACID – BASE ABNORMALITIES 4 
Common medications associated with electrolyte and acid –base abnormalities 
Pathoetiology            Medication    Clinical Findings     Treatment 
Hyponatremia   
(ADH secretion 
and sensitivity) 
Thiazide diuretics, 
Chlorpropamide, 
Vincristine, 
Intravenous 
cyclophophamide, 
Cytoxan, clofibrate, 
narcotics, 
haloperidol, 
thioridazine, 
amitriptyline, 
fluphenazine, 
NSAIDS, 
acetaminophen 
 
UOsm is less than 
maximally diluted in 
presence of low serum 
Na+ 
Discontinue 
medication. 
Consider fluid 
Restriction. 
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                                                 Table – 5 
Hypokalemia / 
Hypomagnesemia 
(increased urinary 
excretion) 
 
Gentamicin, 
cisplatin, diuretics, 
carboplatin, 
nedaplatin 
Increased urinary 
excretion of K+ and 
Mg2+ despite low 
serum levels. 
Discontinue 
medication, 
Replace K+ and Mg2+ 
Hyperkalemia 
(antialdosterone 
or antiadrenergic 
effect; blocking 
sodium channels 
ACEIs,  beta-
blockers, 
 NSAIDS, K+sparing 
diuretics, heparin, 
trimethoprin, 
ciclosporin, 
pentamidine 
Hyperchloremic 
metabolic acidosis with 
or without hypokalemia 
Discontinue 
medication, 
Supportive treatment, 
HCO3 replacement if 
necessary 
Renal tubular 
acidosis 
(decreased 
aldosterone levels 
and response) 
Ciclosporin, 
tacrolimus 
Hyperkalemia 
hyperchloremic, 
metabolic acidosis 
Treat hyperkalemia, 
Consider HCO3 
therapy, low K+ diet, 
avoid concurrent 
medications with 
hyperkalemia. 
Metabolic 
acidosis 
(increased K+and 
H+ secretion in 
distal nephron) 
 
Loop and thiazide 
diuretics 
Alkalemia, 
hypokalemia,hyperchlor
emia 
Discontinue 
medication, volume 
replacement if 
necessary 
Nephrogenic 
diabetes insipidus 
(decreased ADH 
response in 
collecting tubule) 
 
Lithium, 
demeclocycline, 
cyclophosphamide, 
 ifosfamide, 
vincristine, cidofovir 
tenofovir, 
didanosine, foscarnet 
Polyuria, unresponsive 
to ADH 
Discontinue 
medication, supportive 
therapy 
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Renal Vascular Alterations. 
 
Systemic polyarteritis nodosa with involvement of small and medium- sized 
renal arteries found by methamphetamine abuse. Patients may have hematuria, 
proteinuria, renal insufficiency and hypertension. Renal and visceral vascular 
aneurysms can be seen in angiography. The pathogenesis may be a toxic reaction (or) 
the result of associated hepatitis B infection. Penicillin and sulfonamide therapies also 
cause polyarteritis nodosa. Thrombotic microangiopathy (hemolytic-uremic 
syndrome, thrombotic thrombocytopenic purpura ) resulting in thrombus formation in 
the renal vasculature has been seen in drugs such as oral contraceptive agents, 
cicosporine, mitomycin C, cisplatin and quinine. Nephrotoxicity has occurred in long 
term- therapy with mitomycin C alone and in combination with cisplatin, 5- 
flurouracil, bleomycin, and a vinca alkaloid. Microangiopathic hemolytic anemia and 
thrombocytopenia are usually present.  
 
Cholestrol embolic from large atherosclerotic arteries to small renal arteries 
and arterioles can induce an inflammatory obliterative vascular lesion with renal 
failure due to ischemia. This commonly occurs following invasive procedures, may 
also with thrombolytic (or) anticoagulant therapies, which remove thrombus 
formation over ulcerative atherscleotic plaques. 
 
Glomerular Alterations: 
Nephrotic syndrome and glomerulonephritis: 
 
The nephrotic syndrome, defined as proteinuria greater than 3.5g/d, with (or) 
without renal insufficiency is the manifestation of glomerular damage. Minimal 
change nephrotic syndrome is characterized by normal glomeruli by light microscopy. 
Drug induced minimal change nephropathy is accompanied by interstitial nephritis 
and is most common during NSAID therapy. Ampicillin, rifampicin, phenytoin, and 
lithium have also been implicated. 
 
The pathogenesis is unknown, but nephrotic range proteinuria due to NSAID 
therapy is frequently associated with T- lymphocytic interstitial infiltrate suggesting 
disordered cell- mediated immunity. These cells may release lymphokines that 
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increase glomerular capillary permeability to proteins. Proteinuria usually resolves 
rapidly after discontinuation of the offending drug. Prednisolone therapy may resolve 
this lesion. 
 
Focal segmental glomerulosclerosis is the predominant renal lesion in 
acquired immunodeficiency syndrome (AIDS) patients and result from human 
immunodeficiency virus (HIV) or heroin abuse. Glomerulosclerosis due to HIV 
infection may be distinguished from heroin nephropathy tubuloreticular structures and 
poorer prognosis. 
 
Membranous nephropathy, the most common drug – induced glomerular 
lesion, is a immune – mediated disorder characterized by immune complex deposition 
along glomerular capillary loops. Parenteral gold is most common cause that too oral 
gold therapy for rheumatoid arthritis. The pathogenesis may involve damage to 
proximal tubule epithelium with antigen release, antibody formation and glomerular 
immune complex deposition. Renal function is preserved and proteinuria resolves 
within 6- 39 months of discontinuing gold therapy. Mercury in topical skin 
preparations and industrial vapours as well as penicillamine cause membranous 
nephropathy and appears to be immune mediated. 
 
Membranoproliferative gomerulonephritis is a rare consequence of drug 
therapy that is commonly associated with hydralazine- induced systemic lupus 
erythematosus. Other drug induced glomerular lesions include penicillamine therapy 
and combined interleukin-2 and interferon – alpha therapy. Glomerular amyloidosis 
has been associated with heroin abuse particularly inusers who inject subcutaneously. 
The pathogenesis may be immune stimulation from chronic skin inflammation. 
 
Acute tubular Necrosis: 
 
Acute necrosis of renal tubular epithelium is the most common mechanisms 
responsible for drug induced renal insufficiency. Subclincal manifestations include 
tubular proteinuria and enzymuria. Clincal toxicity becomes apparent as a rise in 
serum creatinine and BUN concentrations, a decline in creatinine clearance and 
disturbances of renal tubular electrolyte and water handling. Repititve therapy causing 
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recurrent subclincal toxicity can have cumulative effects resulting in chronic 
tubulointerstitial disease. The mechanism is unclear. The GFR decrease 
proportionately more than renal blood flow decreases, suggesting that renal ischemia 
in not the primary mechanism.  
 
Other mechanisms include, 
- a shunt of blood away from the glomerulus 
- reduction of glomerular capillary filtration pressure 
- decreased permeability of glomerular filtration surface 
- obstruction of tubular flow by damaged epithelial cells and cellular debris 
- backleak of the glomerular filtrate across damaged tubular epithelia into the 
systemic circulation. 
 
The mechanism may depend on the specific nephrotoxic drug. The important 
drugs include aminoglycosides, radiographic contrast media, cisplatin and 
amphotericin B. 
 
Urinary findings 13 :- The onset of injury may not be readily detected because urine 
volume may be normal at first, but if the offending drug is continued , oliguria may 
ensue. Urine microscopy shows dark granular casts and renal epithelial cell casts, 
while the fractional excretion of sodium is often more than 2% to 3%. (Normal value 
< 1%). 
 
Tubulointerstitial Disease: 10 
Acute Allergic Interstitial Nephritis 
 
 Acute allergic interstitial nephritis is common and the underlying cause for    
3 – 14% of all cases of renal failure. Methicillin allergic interstitial nephritis has been 
best characterized. Clinical signs occurred about 17 days ( ranging from 2 – 44 days ) 
after initiation of therapy and includes fever, maculopapular rash, eosinophilia, pyuria 
and haematuria, low- level proteinuria and oliguria. Eosinophiluria has been 
considered an important marker of allergic interstitial nephritis. Anaemia, 
leucocytosis and elevated Ig E levels, as well as tubular dysfunction, including renal 
tubular acidosis, hyperkalemia, salt wasting and concentrating defects may also occur. 
Department of Pharmacy Practice, K.M.C.P, Madurai  Page 20 
 
Allergic interstitial nephritis due to NSAID therapy has a different clinical 
presentation. A concomitant nil lesion nephrotic syndromes are characteristic. 
Cytokine therapy induces a unique nephropathy usually hemodynamically mediated 
due to systemic capillary leak syndrome. Acute interstitial nephritis has occurred 
during leukocyte A interferon therapy for mycosis fungoides and also during adaptive 
cancer immunotherapy with interleukin – 2 (IL – 2 ) and lymphokine – activated killer 
(LAK) cells, causing predominantly T- lymphocytic renal interstitial infiltrate 
combined therapy with alpha human interferon and human granulocyte colony 
stimulating factor(rh G – CSF) has also been associated with ARF and consistent with 
allergic interstitial nephritis. 
 
The renal pathology of allergic interstitial nephritis is a diffuse (or) focal 
interstitial infiltrate of lymphocytes, plasma cells eosinophils and occasional 
polymorphonuclear neutrophils. Granulomas may occur. Patchy peritubular 
inflammation and epithelial cell atrophy with tubular necrosis is also present.    
 
The pathogenesis is an allergic hypersensitivity response. In certain cases a 
humoral, antibody mediated mechanism may be involved as indicated by the 
occasional presence of circulating antibody to a drug hapten- tubular basement 
membrane complex, low serum complement levels and tubular basement deposition 
of Ig G and component. Moreover, a cell mediated mechanism is absent and the 
presence of a predominantly T- lymphocyte infiltrate with an increased helper to 
suppressor cell ratio. The pathogenesis of NSAID interstitial nephritis also involves T 
–lymphocytes , in response to altered prostaglandin synthesis. 
 
Urinary findings :- 13 include white blood cells, and white cell casts. The fractional 
excretion of sodium is often above 1% due to tubular damage, though lower values 
may be seen if there is associated volume depletion. Protein excretion is mild in most 
cases, although some elderly patients and those with NSAID – induced acute 
interstitial nephritis may have proteinuria in the nephritic range (>3g / 24hrs). 
 Some patients may have signs of tubulointerstitial damage such as those with 
Fanconi syndrome (tubular proteinuria, glucosuria, bicarbonaturia, phosphaturia and 
aminoaciduria ) and renal tubular acidosis. 
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Prompt and accurate diagnosis of allergic interstitial nephritis is important 
since failure to stop the offending drug can result in chronic renal insufficiency. The 
presence of fever, rash, eosinophilia and eosinophiluria are not reliable because one 
(or) more of them are frequently absent. Alternatively, gallium reveal imaging is a 
sensitive but nonspecific diagnosis technique. Other interstitial and glomerular lesions 
including pyelonephritis, nil lesion nephritic syndrome cholesterol embolization  can 
give positive seams limiting the usefulness of this test. Treatment with corticosteroids 
in a dose of 0.5 – 1mg/kg body weight for 1 – 4 weeks may shorten the duration and 
improve the extent of renal function recovery.   
 
Drugs causing acute interstitial nephritis 5 
 
 
                                                             Table-6 
  
Class Name of Drug 
Penicillins 
 
Other antibiotics 
 
 
 
 
NSAIDs 
 
 
 
Diuretics 
 
Heavy metals 
Miscellaneous 
 
Methicillin, ampicillin, cabenicillin, 
Nafcilin, toxacillin amoxicillin. 
Sulfonamides,  polymixin, 
 cephalosporins, rifampicin, 
erythromycin, cotrimoxazole, 
 lincomycin, quinolones, 
vancomycin. 
Aspirin, fenoprofen, benoxapofen, 
Glafenine, lbuprofen, indomethacin 
Mefenamic acid, phenyl butazone, 
naproxen, tolmetin. 
Thiazides, furosemide, ethacrynic acid, 
triamterene, indapamide. 
Gold, bismuth 
Allopurinol, amphetamine 
 azathioprine, captopril,  
cimetidine, clofibrate, phenytoin  
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Chronic interstitial nephritis 10 
 
Lithium and cyclosporine cause progressive and irreversible nephropathy. 
Streptozotoin and other anti- neoplastic nitrosoureas can alsi induce dose dependent 
chronic tubulointerstitial disease. 
 
Lithium therapy cause renal tubular lesions, including chronic 
tubulointerstitial nephritis, impaired ability to concentrate urine, incomplete distal 
renal tubular acidosis and acute renal failure. Impaired ability to concentrate urine is 
due to dose related decrease in collecting duct response to anti- diuretic hormone. 
This results from impaired formation of cellular CAMP in response to anti- diuretic 
hormone and can frequently be reversed by discontinuation of lithium therapy (or) 
ameliorated with amiloride during continued lithium therapy. Lithium induced ARF 
occurs during episodes of lithium intoxication. The pathogenesis include dehydration 
secondary to nephrogenic diabetes insipidus as well as direct proximal and  distal 
tubular cell toxicity. Severe renal insufficiency may occur and can be reversible with 
supportive care, including dialysis therapy to reduce toxic serum lithium 
concentrations. The renal lesions include interstitial fibrosis with focal tubular atrophy 
and glomerular lesions. The duration of lithium therapy has correlated with decline in 
the GFR suggesting the pathogenesis may involve direct lithium toxicity. Alternative 
mechanisms include cumulative effects of acute episodes of lithium toxicity, the use 
of concomitant drugs such as neuroleptics (or) ACEI’s and concurrent renal 
tubulointerstitial disease. Preventive measures include maintenance of lithium serum 
concentrations in the therapeutic range, avoidance of dehydration and close 
monitoring of renal function including urinary concentrating ability. 
 
Cyclosporine can also cause interstitial fibrosis and chronic irreversible renal 
insufficiency after approximately 6 – 12 months of therapy. This is a major limitation 
as 10% of cardiac transplant patients develop s end stage renal failure with prolonged 
high doses. The pathogenesis involves sustained renal endothelial cell injury and 
ischemia( or) direct tubular toxicity. Ciclosporine induced interstitial matrix synthesis 
and accumulation, apparently due to increased activity of cytokines, peptide growth 
factors (or) thromborane may also contribute. The risk of chronic interstitial renal 
disease appears to be lessened with the current lower dose therapy.   
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Papillary Necrosis  
 
Chronic excessive consumption of combination analgesics containing 
phenacetin can cause chronic renal tubulointerstitial disease with papillary necrosis 
and lead to increased hypertension and atherosclerotic cardiovascular disease. In high 
dose dapsone therapy, used frequently recently for P. carini infections during the HIV 
epidermic , may also cause papillary necrosis. In addition, the incidence of lower 
urinary tract transitional cell carcinoma is increased in patients with heavy use of 
phenacetin. Analgesic nephropathy evolves insidiously over years with clinical 
expression following a cumulative phenacetin ingestion of 3kg or more. 
 
Renal manifestations include impaired maximal urinary concentration, sterile 
pyuria , microscopic haematuria, proteinuria and hypertension. Creatinine clearance 
declines slowly. Upper gastro- intestinal irritation from analgesics with blood loss 
leading to anaemia has been characteristic. The diagnosis is confirmed by intravenous 
pyelography with demonstration of papillary necrosis (or) by computed tomography 
(CT) scan, which shows decreased renal mass and bumpy contours (or) pappilary 
calcifications. In addition, chronic interstitial disease and papillary nacrosis may occur 
with the use of NSAIDS alone, particularly in males. 
 
The biochemical mechanism appears to involve metabolism of phenacetin to 
acetaminophen, when oxidized to toxic free radicals that are concentrated in the 
pappila during urinary concentration. The ability of the kidney to oxidize 
acetaminophen may be due to lack of renal cytochrome P-450, co-oxidation of 
acetaminophen may occur with renal prostaglandin synthesis. Papillary ischemia 
results from the ability of both salicylate and acetaminophen to inhibit renal 
medullary synthesis of vasodilatory prostaglandins. Impaired cellular energy 
production results from ability of salicylate to uncouple mitochondrial oxidative 
phosphorylation. 
 
Prevention has depended primarily on public health efforts to restrict the sale 
of phenacetin and combination analgesics; however OTC analgesic use yet causes 
nephrotoxicity. Individuals requiring chronic analgesic therapy may reduce their risk 
by limiting the total dose, avoiding the combined use of two (or) more analgesics, 
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maintaining adequate hydration to prevent renal ischemia and decrease the papillary 
concentration of toxic substances. Treatment of established nephrotoxicity requires 
cessation of analgesic consumption, which can prevent progression and improve renal 
function. Patients should be carefully evaluated tor associated transitional cell 
carcinoma of the renal pelvis, calyces, ureters and bladder. Carcinoma may present 
years after analgesic therapy in diagnosed. 
 
Obstructive Nephropathy 
Renal tubular obstruction     
 
 In drug induced renal injury, renal tubular obstruction can be caused by intra-
tubular precipitation of tissue degradation products as drugs (or) their metabolites, 
acute uric acid nephropathy following chemotherapy, for hemolytic malignancies is 
the most common cause. Acute oliguric (or) anuric renal injury develops rapidly. The 
diagnosis is supported by a urine uric acid to creatinine ratio greater than one. Uric 
acid precipitation can be prevented by pre-treatment hydration, urinary alkalinization 
and administration of allopurinol. Uric acid nephropathy was also seen at incitation of 
therapy with uricosuric NSAIDS. 
 
Induced muscle necrosis, non- traumatic rhabdomyolysis, is an important 
cause of renal injury in part to intratubular precipitation of myoglobin. Drug – 
induced rhabdomyolysis may result from pressure necrosis following alcohol (or) 
heroin abuse, extreme neuromuscular stimulation and metabolic demands with abuse 
of phencyclidine (or) therapy with adrenergic agents including terbutaline and 
vasoconstriction and muscle ischemia due to abuse of cocaine (or) therapeutic 
vasopressin infusion . rhabdomyolysis occurred during lovastatin therapy for 
hypercholesterolemia, also with erythromycin, gemfibrozil, niacin and cyclosporine. 
Mechanism appears to be accumulation of myotoxic levels of lovastatin due to 
competitive inhibition by cyclosporine for metabolis through the cytochrome P-450 
system. 
 
Precipitation of drugs (or) their metabolites in concentrated acidic urine 
particularly with previous generations of sulphonamides and this problem is resolved 
recently with more soluble sulphonamides . It may occur during acetazolamide 
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therapy and has become more frequent with resurgence with sulphadiazine therapy, 
toxoplasmosis in AIDS patients. Methotrexate and its metabolite 7- 
hydroxymethotrexate which is less soluble have also precipitated in urine and cause 
obligaanuric renal failure during high dose chemotherapy.  
 
It cab be prevented largely by hydration and alkalization of the urine. 
Acyclovir given intravenously may cause intra- tubular obstruction and ARF. This 
can be avoided largely and not completely by adminstation dosage slowly with 
adequate hydration. But ARF is not seen in oral acyclovir. 
 
Massive administration of ascorbic acids, calcium antacids can also result in 
obstruction of renal tubules. Oxalate, a poorely soluble ascorbic acid metabolite, can 
also precipitate when administered to patients with ARF (or) congenital nephrotic 
syndrome.   Low molecular weight dextran therapy for volume expansion and 
sheological effects caused renal injury, possibly by intra- tubular precipitation of 
filtered dextran. Triamterene may also precipitate in renal tubules and cause renal 
failure. Renal injury due to intra- tubular precipitation of tissue degradation products 
(or) metabolites can be largely prevented and treated by maintaining a high urine 
volume and urinary alkalinazation. Therapeutic agents not intended for systemic 
administration can cause renal failure in rare cases, apparently by intra- tubular (or) 
intra-renal precipitation. 
 
Extra- renal Urinary tract Obstruction 
 
Drug therapy may also cause renal insufficiency due to lower urinary tract 
obstruction. Ureteral obstruction can be caused by calculi (or) retroperitoneal fibrosis 
due to analgesic, methysergide (or) radiation therapy. Bladder dysfunction with 
urinary outflow obstruction can result, particularly in males with prostatic 
hypertrophy, from anti-cholinergic drugs including tricyclic antidepressants. In 
particular, disopyramide phosphate, an antiarrythmic drug with anticholinergic 
effects, has caused renal injury due to urinary retention. Bladder outlet and ureteral 
obstruction may result from bladder fibrosis following hemorrgagic cystitis with 
cyclophosphamide (or) ifosfamide therapy.  
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Drug-Induced Nephrotoxicity 
Drugs are a common source of acute kidney injury. Compared with 30 years 
ago, the average patient today is older, has more comorbidities, and is exposed to 
more diagnostic and therapeutic procedures with the potential to harm kidney 
function. Drugs shown to cause nephrotoxicity exert their toxic effects by one or more 
common pathogenic mechanisms. Drug-induced nephrotoxicity tends to be more 
common among certain patients and in specific clinical situations. Therefore, 
successful prevention requires knowledge of pathogenic mechanisms of renal injury, 
patient-related risk factors, drug-related risk factors, and preemptive measures, 
coupled with vigilance and early intervention. Some patient-related risk factors for 
drug-induced nephrotoxicity are age older than 60 years, underlying renal 
insufficiency (e.g., glomerular filtration rate of less than 60 mL per minute per 1.73 
m2), volume depletion, diabetes, heart failure, and sepsis. General preventive 
measures include using alternative non-nephrotoxic drugs whenever possible; 
correcting risk factors, if possible; assessing baseline renal function before initiation 
of therapy, followed by adjusting the dosage; monitoring renal function and vital 
signs during therapy; and avoiding nephrotoxic drug combinations.  
CLINICAL RECOMMENDATION 
Patients at highest risk of drug-induced nephrotoxicity are those with one or 
more of the following: age older than 60 years, baseline renal insufficiency (e.g., GFR 
< 60 mL per minute per 1.73 m2), and volume depletion, multiple exposures to 
nephrotoxins, diabetes, heart failure, and sepsis. 
Assess baseline renal function using the MDRD or Cockcroft-Gault GFR 
estimation equation and consider a patient's renal function when prescribing a new 
drug. 
Monitor renal function and vital signs after starting or increasing the dose of 
drugs associated with nephrotoxicity, especially when used chronically. 
Pathogenic Mechanisms 
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Most drugs found to cause nephrotoxicity exert toxic effects by one or more 
common pathogenic mechanisms. These include altered intraglomerular 
hemodynamics, tubular cell toxicity, inflammation, crystal nephropathy, 
rhabdomyolysis, and thrombotic microan-giopathy.7–9 Knowledge of offending drugs 
and their particular pathogenic mechanisms of renal injury is critical to recognizing 
and preventing drug-induced renal impairment (Table 110–31). 
Drugs Associated with Nephrotoxicity 
DRUGS AND THEIR 
CLASSIFICATION 
PATHOPHYSIOLOGIC 
MECHANISM OF RENAL INJURY 
Analgesics  
1 Acetaminophen, aspirin Chronic interstitial nephritis 
2 Nonsteroidal anti-inflammatory 
drugs 
Acute interstitial nephritis, altered 
intraglomerular hemodynamics, 
chronic interstitial nephritis, 
glomerulonephritis 
Antidepressants/mood stabilizers  
1 Amitriptyline (Elavil*), 
doxepin (Zonalon), fluoxetine 
(Prozac) 
Rhabdomyolysis 
2 Lithium Chronic interstitial nephritis, 
glomerulonephritis, rhabdomyolysis 
Antihistamines  
1 Diphenhydramine (Benadryl), Rhabdomyolysis 
Department of Pharmacy Practice, K.M.C.P, Madurai  Page 28 
 
DRUGS AND THEIR 
CLASSIFICATION 
PATHOPHYSIOLOGIC 
MECHANISM OF RENAL INJURY 
doxylamine (Unisom) 
Antimicrobials  
1 Acyclovir (Zovirax) Acute interstitial nephritis, crystal 
nephropathy 
2 Aminoglycosides Tubular cell toxicity 
3 Amphotericin B (Fungizone*; 
deoxycholic acid formulation 
more so than the lipid 
formulation) 
Tubular cell toxicity 
4 Beta lactams (penicillins, 
cephalosporins) 
Acute interstitial nephritis, 
glomerulonephritis (ampicillin, 
penicillin) 
5 Foscarnet (Foscavir) Crystal nephropathy, tubular cell 
toxicity 
6 Ganciclovir (Cytovene) Crystal nephropathy 
7 Pentamidine (Pentam) Tubular cell toxicity 
8 Quinolones Acute interstitial nephritis, crystal 
nephropathy (ciprofloxacin [Cipro]) 
Department of Pharmacy Practice, K.M.C.P, Madurai  Page 29 
 
DRUGS AND THEIR 
CLASSIFICATION 
PATHOPHYSIOLOGIC 
MECHANISM OF RENAL INJURY 
9 Rifampin (Rifadin) Acute interstitial nephritis 
1o Sulfonamides Acute interstitial nephritis, crystal 
nephropathy 
11 Vancomycin (Vancocin) Acute interstitial nephritis 
 
 
Antiretrovirals  
1 Adefovir (Hepsera), cidofovir 
(Vistide), tenofovir (Viread) 
Tubular cell toxicity 
2 Indinavir (Crixivan) Acute interstitial nephritis, crystal 
nephropathy 
Benzodiazepines Rhabdomyolysis 
Calcineurin inhibitors  
1 Cyclosporine (Neoral) Altered intraglomerular 
hemodynamics, chronic interstitial 
nephritis, thrombotic microangiopathy 
2 Tacrolimus (Prograf) Altered intraglomerular hemodynamics 
1 Angiotensin-converting enzyme Altered intraglomerular hemodynamics 
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DRUGS AND THEIR 
CLASSIFICATION 
PATHOPHYSIOLOGIC 
MECHANISM OF RENAL INJURY 
inhibitors, angiotensin receptor 
blockers 
 
Cardiovascular agents 
1 Angiotensin-converting enzyme 
inhibitors, angiotensin receptor 
blockers 
Altered intraglomerular hemodynamics 
2 Clopidogrel (Plavix), 
ticlopidine (Ticlid) 
Thrombotic microangiopathy 
3 Statins Rhabdomyolysis 
Chemotherapeutics  
1 Carmustine (Gliadel), 
semustine (investigational) 
Chronic interstitial nephritis 
2 Cisplatin (Platinol) Chronic interstitial nephritis, tubular 
cell toxicity 
3 Interferon-alfa (Intron A) Glomerulonephritis 
4 Methotrexate Crystal nephropathy 
5 Mitomycin-C (Mutamycin) Thrombotic microangiopathy 
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DRUGS AND THEIR 
CLASSIFICATION 
PATHOPHYSIOLOGIC 
MECHANISM OF RENAL INJURY 
Contrast dye Tubular cell toxicity 
Diuretics  
1 Loops, thiazides Acute interstitial nephritis 
2 Triamterene (Dyrenium) Crystal nephropathy 
Drugs of abuse  
1 Cocaine, heroin, ketamine 
(Ketalar), methadone, 
methamphetamine 
Rhabdomyolysis 
Herbals  
1 Chinese herbals with 
aristocholic acid 
Chronic interstitial nephritis 
Proton pump inhibitors  
1 Lansoprazole (Prevacid), 
omeprazole (Prilosec), 
pantoprazole (Protonix) 
Acute interstitial nephritis 
 
 
Others 
 
Department of Pharmacy Practice, K.M.C.P, Madurai  Page 32 
 
DRUGS AND THEIR 
CLASSIFICATION 
PATHOPHYSIOLOGIC 
MECHANISM OF RENAL INJURY 
1 Allopurinol (Zyloprim) Acute interstitial nephritis 
2 Gold therapy Glomerulonephritis 
3 Haloperidol (Haldol) Rhabdomyolysis 
4 Pamidronate (Aredia) Glomerulonephritis 
5 Phenytoin (Dilantin) Acute interstitial nephritis 
6 Quinine (Qualaquin) Thrombotic microangiopathy 
7 Ranitidine (Zantac) Acute interstitial nephritis 
8 Zoledronate (Zometa) Tubular cell toxicity 
     Table-7 
ALTERED INTRAGLOMERULAR HEMODYNAMICS 
In an otherwise healthy young adult, approximately 120 mL of plasma is 
filtered under pressure through the glomerulus per minute, which corresponds to the 
glomerular filtration rate (GFR). The kidney maintains or autoregulates 
intraglomerular pressure by modulating the afferent and efferent arterial tone to 
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preserve GFR and urine output. For instance, in patients with volume depletion, renal 
perfusion depends on circulating prostaglandins to vasodilate the afferent arterioles, 
allowing more blood flow through the glomerulus. 
At the same time, intraglomerular pressure is sustained by the action of 
angiotensin-II–mediated vasoconstriction of the efferent arteriole. Drugs with 
antiprostaglandin activity (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]) or 
those with antiangiotensin-II activity (e.g., angiotensin-converting enzyme [ACE] 
inhibitors, angiotensin receptor blockers [ARBs]) can interfere with the kidneys' 
ability to autoregulate glomerular pressure and decrease GFR.10,32 Other drugs, such 
as calcineurin inhibitors (e.g., cyclosporine [Neoral], tacrolimus [Prograf]), cause 
dose-dependent vasoconstriction of the afferent arterioles, leading to renal impairment 
in at-risk patients.11 
TUBULAR CELL TOXICITY 
Renal tubular cells, in particular proximal tubule cells, are vulnerable to the 
toxic effects of drugs because their role in concentrating and reabsorbing glomerular 
filtrate exposes them to high levels of circulating toxins.12 Drugs that cause tubular 
cell toxicity do so by impairing mitochondrial function, interfering with tubular 
transport, increasing oxidative stress, or forming free radicals.8,13 Drugs associated 
with this pathogenic mechanism of injury include aminoglycosides, amphotericin B 
(Fungizone; brand not available in the United States), antiretrovirals (adefovir 
[Hepsera], cidofovir [Vistide], tenofovir [Viread]), cisplatin (Platinol), contrast dye, 
foscarnet (Foscavir), and zoledronate (Zometa).12–14 
 
INFLAMMATION 
Drugs can cause inflammatory changes in the glomerulus, renal tubular cells, 
and the surrounding interstitium, leading to fibrosis and renal scarring. 
Glomerulonephritis is an inflammatory condition caused primarily by immune 
mechanisms and is often associated with proteinuria in the nephrotic range.12 
Medications such as gold therapy, hydralazine (Apresoline; brand not available in the 
United States), interferon-alfa (Intron A), lithium, NSAIDs, propylthiouracil, and 
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pamidronate (Aredia; in high doses or prolonged courses) have been reported as 
causative agents.12,13,15 
Acute interstitial nephritis, which can result from an allergic response to a 
suspected drug, develops in an idiosyncratic, non–dose-dependent fashion.16 
Medications that cause acute interstitial nephritis are thought to bind to antigens in the 
kidney or act as antigens that are then deposited into the interstitium, inducing an 
immune reaction.16 However, classic symptoms of a hypersensitivity reaction (i.e., 
fever, rash, and eosinophilia) are not always observed.13,16 Numerous drugs have been 
implicated, including allopurinol (Zyloprim); antibiotics (especially beta lactams, 
quinolones, rifampin [Rifadin], sulfonamides, and vancomycin [Vancocin]); antivirals 
(especially acyclovir [Zovirax] and indinavir [Crixivan]); diuretics (loops, thiazides); 
NSAIDs; phenytoin (Dilantin); proton pump inhibitors (especially omeprazole 
[Prilosec], pantoprazole [Protonix], and lansoprazole [Prevacid]); and ranitidine 
(Zantac).13,16–19 
Chronic interstitial nephritis is less likely than acute interstitial nephritis to be 
drug induced; it is also insidious in onset, and signs of hypersensitivity are often 
lacking.20 Drugs associated with this mechanism of nephrotoxicity include calcineurin 
inhibitors (e.g., cyclosporine, tacrolimus), certain chemotherapy agents, Chinese 
herbals containing aristocholic acid, and lithium.11,20,21 Chronic interstitial nephritis 
has been reported with analgesics such as acetaminophen, aspirin, and NSAIDs when 
used chronically in high dosages (i.e., more than 1 gram daily for more than two 
years) or in patients with preexisting kidney disease.22,23 Early recognition is 
important because chronic interstitial nephritis has been known to progress to end-
stage renal disease.20 Diagnosis may be difficult because most patients do not 
consider over-the-counter preparations to be medications and tend to underreport 
frequency of use. 
 
CRYSTAL NEPHROPATHY 
Renal impairment may result from the use of drugs that produce crystals that 
are insoluble in human urine. The crystals precipitate, usually within the distal tubular 
lumen, obstructing urine flow and eliciting an interstitial reaction.13 Commonly 
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prescribed drugs associated with production of crystals include antibiotics (e.g., 
ampicillin, ciprofloxacin [Cipro], sulfonamides); antivirals (e.g., acyclovir, foscarnet, 
ganciclovir [Cytovene]); indinavir; methotrexate; and triamterene (Dyrenium).12,13,24 
The likelihood of crystal precipitation depends on the concentration of the drug in the 
urine and the urinary pH.24 Patients most at risk of crystal nephropathy are those with 
volume depletion and underlying renal insufficiency.24 
Chemotherapy for lymphoproliferative disease, leading to tumor lysis 
syndrome with uric acid and calcium phosphate crystal deposition, has also been 
associated with renal failure.25 
 
RHABDOMYOLYSIS 
Rhabdomyolysis is a syndrome in which skeletal muscle injury leads to lysis 
of the myocyte, releasing intracellular contents including myoglobin and creatine 
kinase into the plasma. Myoglobin induces renal injury secondary to direct toxicity, 
tubular obstruction, and alterations in GFR.26 Drugs may induce rhabdomyolysis 
directly secondary to a toxic effect on myocyte function, or indirectly by predisposing 
the myocyte to injury.26,27 Clinical manifestations of rhabdomyolysis include 
weakness, myalgia, and tea-colored urine.27 
Statins are the most recognizable agents associated with rhabdomyolysis, but 
more than 150 medications and toxins have been implicated.26 Rhabdomyolysis with 
statin monotherapy is rare, with an average reported incidence of 0.44 per 10,000 
person-years of therapy.28 Many drugs of abuse, such as cocaine, heroin, ketamine 
(Ketalar), methadone, and methamphetamine, have been reported to cause 
rhabdomyolysis.26,27 Drugs and alcohol are causative factors in up to 81 percent of 
cases of rhabdomyolysis, and up to 50 percent of patients subsequently develop acute 
renal failure.29 
THROMBOTIC MICROANGIOPATHY 
In thrombotic microangiopathy, organ damage is caused by platelet thrombi in 
the microcirculation, as in thrombotic thrombocytopenic purpura.30 Mechanisms of 
renal injury secondary to drug-induced thrombotic microangiopathy include an 
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immune-mediated reaction or direct endothelial toxicity.30 Drugs most often 
associated with this pathogenic mechanism of nephrotoxicity include antiplatelet 
agents (e.g., clopidogrel [Plavix], ticlopidine [Ticlid]), cyclosporine, mitomycin-C 
(Mutamycin), and quinine (Qualaquin).30,31 
Preventing Drug-Induced Renal Impairment 
Drug-induced nephrotoxicity tends to occur more frequently in certain patients 
and in specific clinical situations. Therefore, successful prevention requires 
knowledge of patient-related risk factors, drug-related risk factors, and preemptive 
measures, coupled with vigilance and early intervention.7,33 Prevention strategies 
should target the prescribing and monitoring of potential nephrotoxins in at-risk 
patients. Whenever possible, risk factors should be corrected before drugs associated 
with nephrotoxicity are prescribed. 
PATIENT-RELATED RISK FACTORS 
Patient-related risk factors vary somewhat depending on the offending drug. 
However, some risk factors are common to all nephrotoxins and include age older 
than 60 years, underlying renal insufficiency (e.g., GFR of less than 60 mL per minute 
per 1.73 m2), intravascular volume depletion, exposure to multiple nephrotoxins, 
diabetes, heart failure, and sepsis (Table 2).1–3,7,34,35 There are conflicting reports 
about the influence of race and genetic variation, as well as whether men are at greater 
risk of developing acute renal failure compared with women.34 The risk of acute renal 
failure increases with the presence of each additional risk factor. Patients with any of 
these risk factors, especially those who have more than one risk factor (e.g., a patient 
with diabetes and heart failure), should be closely monitored for changes in renal 
function when a medication is added or a dosage is increased. 
 
Patient-Related Risk Factors for Drug-Induced Nephrotoxicity 
 
• “Absolute” or “effective” intravascular volume depletion 
• Age older than 60 years 
• Diabetes 
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• Exposure to multiple nephrotoxins 
• Heart failure 
• Sepsis 
• Underlying renal insufficiency (glomerular filtration rate < 60 mL per minute 
per 1.73 m2) 
 
Both “absolute” and “effective” intravascular volume depletion are risk factors 
for drug-induced renal impairment. Absolute intravascular volume depletion may 
occur in patients who have gastroenteritis, chronic diarrhea, aggressive diuresis, or 
poor oral intake.10 Effective intravascular volume is the volume of blood perceived by 
baroreceptors located in the right atrium and the kidney. Decreased effective 
circulating blood volume results from sequestration of fluid into thirdspace 
compartments and is associated with sepsis, heart failure, ascites, or pancreatitis.7,36 
 
DRUG-RELATED RISK FACTORS 
Certain drugs are inherently nephrotoxic and include aminoglycosides, 
amphotericin B, cisplatin, contrast dye, and cyclosporine.7,34 For others, such as those 
associated with chronic interstitial nephritis and crystal deposition, nephrotoxicity is 
dose dependant or related to prolonged duration of treatment.24 Combination therapy 
with multiple nephrotoxins can result in synergistic nephrotoxicity, thus increasing 
the risk of renal injury.7 Specific preventive measures unique to some of these drugs 
are highlighted in Table 3.7,10–13,20–24,32,37,38 
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Patient-Related Risk Factors and Specific Prevention Strategies for Selected Agents 
MEDICATIONS RISK FACTORS PREVENTION STRATEGIES 
Drugs altering intraglomerular hemodynamics 
ACE inhibitors, 
ARBs, NSAIDs 
Underlying renal insufficiency; 
intravascular volume depletion; age 
older than 60 years; concomitant use 
of ACE inhibitors, ARBs, NSAIDs, 
cyclosporine (Neoral), or tacrolimus 
(Prograf) 
Use analgesics with less 
prostaglandin activity 
(acetaminophen, aspirin, 
sulindac [Clinoril], nabumetone 
[Relafen; brand not available in 
the United States]) 
Correct volume depletion before 
initiation of drug, especially if 
used on a chronic basis 
Monitor renal function and vital 
signs following initiation or 
dose escalation, especially if 
used in at-risk patients 
Cyclosporine, 
tacrolimus 
As above, plus: excessive dose, 
concomitant use with other 
nephrotoxic drugs or drugs that 
inhibit cyclosporine or tacrolimus 
metabolism 
Monitor serum drug 
concentrations and renal 
function 
Use lowest effective dose 
Drugs associated with tubular cell toxicity  
Aminoglycosides Underlying renal insufficiency, Use extended-interval dosing 
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duration of therapy > 10 days, trough 
concentrations > 2 mcg per mL, 
concomitant liver disease, 
hypoalbuminemia 
Administer during active period 
of day 
Limit duration of therapy 
Monitor serum drug levels and 
renal function two to three times 
per week 
Maintain trough levels ≤ 1 mcg 
per mL 
Amphotericin B  Underlying renal insufficiency, rapid 
infusion, large daily dosage, 
deoxycholate formulations more so 
than lipid formulations, prolonged 
duration of therapy 
Saline hydration before and 
after dose administration 
ACE inhibitors, 
ARBs, NSAIDs 
Underlying renal insufficiency; 
intravascular volume depletion; age 
older than 60 years; concomitant use 
of ACE inhibitors, ARBs, NSAIDs, 
cyclosporine (Neoral), or tacrolimus 
(Prograf) 
Use analgesics with less 
prostaglandin activity 
(acetaminophen, aspirin, 
sulindac [Clinoril], nabumetone 
[Relafen; brand not available in 
the United States]) 
Correct volume depletion before 
initiation of drug, especially if 
used on a chronic basis 
Monitor renal function and vital 
signs following initiation or 
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dose escalation, especially if 
used in at-risk patients 
Cyclosporine, 
tacrolimus 
As above, plus: excessive dose, 
concomitant use with other 
nephrotoxic drugs or drugs that 
inhibit cyclosporine or tacrolimus 
metabolism 
Monitor serum drug 
concentrations and renal 
function 
Use lowest effective dose 
Drugs associated with tubular cell toxicity  
Aminoglycosides Underlying renal insufficiency, 
duration of therapy > 10 days, 
trough concentrations > 2 mcg per 
mL, concomitant liver disease, 
hypoalbuminemia 
Use extended-interval dosing 
Administer during active period 
of day 
Limit duration of therapy 
Monitor serum drug levels and 
renal function two to three times 
per week 
Maintain trough levels ≤ 1 mcg 
per mL 
Amphotericin B 
(Fungizone; brand 
not available in the 
United States) 
Underlying renal insufficiency, 
rapid infusion, large daily dosage, 
deoxycholate formulations more so 
than lipid formulations, prolonged 
duration of therapy 
Saline hydration before and 
after dose administration 
Consider administering as a 
continuous infusion over 24 
hours 
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Use liposomal formulation 
Limit duration of therapy 
Contrast dye Underlying renal insufficiency, age 
older than 70 years, diabetes, heart 
failure, volume depletion, repeated 
exposures 
Use low-osmolar contrast in the 
lowest dose possible and avoid 
multiple procedures in 24 to 48 
hours 
0.9% saline or sodium 
bicarbonate (154 mEq per L) 
infusion before and after 
procedure 
Withhold NSAIDs and diuretics 
at least 24 hours before and 
after procedure 
Monitor renal function 24 to 48 
hours postprocedure 
Consider acetylcysteine 
preprocedure 
Drugs associated with chronic interstitial nephropathy 
Acetaminophen, 
aspirin, NSAIDs 
History of chronic pain, age older 
than 60 years, female sex, 
cumulative consumption of 
analgesic > 1 gram per day for 
more than two years 
Avoid long-term use, 
particularly of more than one 
analgesic 
Use alternate agents in patients 
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with chronic pain 
Lithium Elevated drug levels Maintain drug levels within the 
therapeutic range 
Avoid volume depletion 
Drugs associated with crystal nephropathy  
Acyclovir 
(Zovirax), 
methotrexate, sulfa 
antibiotics, 
triamterene 
(Dyrenium) 
Volume depletion, underlying 
renal insufficiency, excessive dose, 
intravenous administration 
Discontinue or reduce dose 
Ensure adequate hydration 
Establish high urine flow 
Administer orally 
Table-8 
 Contrast-induced nephropathy is reported to be the third most common cause 
of acute renal failure in hospitalized patients.2 The exact incidence, however, varies 
depending on study design, type and dose of contrast used, and presence of acute 
renal failure risk factors and other comorbidities.37 The risk of contrast-induced 
nephropathy is highest in patients with chronic kidney disease (i.e., a GFR of  less 
than 60 mL per minute per 1.73 m2), especially in the presence of diabetes.39 Other 
risk factors include dehydration, heart failure, age older than 70 years, and concurrent 
use of nephrotoxic drugs.37 Patients with risk factors for contrast-induced 
nephropathy, especially those who have multiple risk factors, require prophylactic 
interventions before imaging.  Prophylactic interventions studied have included 
normal saline or sodium bicarbonate infusions and acetylcysteine before and after 
imaging.38,40 However, the role of acetylcysteine has yet to be defined because clinical 
trial results have been inconsistent.37 
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PREVENTIVE MEASURES 
General preventive measures include using equally effective but non-
nephrotoxic drugs whenever possible, correcting risk factors for nephrotoxicity, 
assessing baseline renal function before initiating therapy, adjusting the dose of 
medications for renal function, and avoiding nephrotoxic drug combinations (Baseline 
renal function can be estimated at the bedside using the Modification of Diet in Renal 
Disease (MDRD) formula or the Cockcroft-Gault formula in adults and the Schwartz 
formula for children The National Kidney Foundation advocates using the MDRD 
formula for the detection and staging of chronic kidney disease. 
General Measures to Prevent Drug-Induced Nephrotoxicity 
• Medication dosages using the Cockcroft-Gault formula (in adults) or Schwartz 
formula (in children). 
 
• Assess baseline renal function using the MDRD equation, and consider 
patient's renal function when prescribing a new drug.  
 
• Avoid nephrotoxic combinations 
 
• Correct risk factors for nephrotoxicity before initiation of drug therapy. 
 
• Ensure adequate hydration before and during therapy with potential 
nephrotoxins. Use equally effective non-nephrotoxic drugs whenever possible. 
 
Formulae to Assess Renal Function and Adjust Medication Dosages 
 
AUTHOR ESTIMATION FORMULA PURPOSE 
MDRD41 eGFR = 186 × serum creatinine (mg per 
dL) −1.154 × age (years) −0.203 × (0.742 if 
patient is female) × (1.210 if patient is 
To assess renal 
function and stage 
chronic kidney 
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AUTHOR ESTIMATION FORMULA PURPOSE 
black) disease44 
Cockcroft 
and Gault42 
Male: eCrCl = ([140 – age (years)] × ideal 
body weight [kg]) ÷ (serum creatinine [mg 
per dL] × 72) 
To adjust drug dosing 
for renal function in 
adults45 
Female: male eCrCl × 0.85 
Schwartz43 eCrCl = (length [cm] × k) ÷ serum 
creatinine (mg per dL) 
To adjust drug dosing 
for renal function in 
children 
k = 0.45 (infants one to 52 weeks of age) 
0.55 (children one to 13 years of age) 
0.70 (males 14 to 17 years of age) 
0.55 (females 14 to 17 years of age) 
Table 9 
eCrCl = estimated creatinine clearance; eGFR = estimated glomerular filtration 
rate; MDRD = Modification of Diet in Renal Disease. 
 
Most drugs that are eliminated  renally do not require dosage adjustment until 
the creatinine clearance falls below 50 mL per minute.46 The preferred formula 
advocated by the U.S. Food and Drug Administration to guide drug dosing in adults is 
the Cockcroft-Gault formula because it has been used in nearly all pharmacokinetic 
studies to generate drug-dosing guidelines.45,47 Compared with the MDRD, the 
Cockcroft-Gault equation tends to overestimate the GFR and may yield different 
results depending on the patient.41 For example, the estimated GFR of a 64-year-old, 
190-lb (86-kg) woman with a serum creatinine level of 1.3 mg per dL (110 µmol per 
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L; normal: 0.8 to 1.4 mg per dL [70 to 120 µmol per L]) is 59 mL per minute using 
the Cockcroft-Gault formula and 44 mL per minute per 1.73 m2 according to the 
MDRD. In this example, both formulas indicate renal insufficiency, but the patient's 
medications most likely would not require a dose adjustment. 
 
Adequate hydration is important to maintain renal perfusion and avoid drug-
induced renal impairment. Whenever possible, volume status should be assessed and 
corrected, if necessary, before initiation of nephrotoxic agents. This is particularly 
true when prescribing medications such as ACE inhibitors, ARBs, and NSAIDs, 
which induce alterations in renal hemodynamics in patients who are significantly 
volume depleted.10,32 Signs of significant intravascular volume depletion include 
orthostatic hypotension, blood pressure of less than 90/60 mm Hg, and decreased skin 
turgor accompanied by a loss of more than 5 percent of baseline body weight.1–4 
Currently, there is no consensus on the optimal solution, volume, or timing of fluids 
to restore renal perfusion.7 
 
A systems approach involving computerized physician order entry and clinical 
decision support may reduce the danger of exposing at-risk patients to nephrotoxins, 
but such systems are greatly underused in the ambulatory setting.48 Forming 
collaborations between those who prescribe drugs and clinical pharmacists is a good 
option and should be pursued and developed, although funding such efforts may be a 
challenge.48 Two reports from the Institute of Medicine recognized that pharmacists 
are an essential resource in safe medication use and that pharmacist-physician-patient 
collaboration is important.49,50 The clinical and economic impact of clinical 
pharmacists in other settings has been extensively reviewed and summarized in the 
literature.51 
 
VIGILANCE 
 
In one large cohort study of Medicare enrollees in the ambulatory setting, 
inadequate laboratory monitoring played a role in 36 percent of all preventable 
adverse drug events.48 In addition, when assessing baseline renal function, physicians 
should consider monitoring serum creatinine levels after starting or increasing the 
dosage of drugs associated with nephrotoxicity, especially those used chronically in 
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patients with multiple risk factors for renal impairment. A systems approach toward 
adopting an electronic medical record may provide a practical method for automated 
monitoring of all patients in general, and patients at risk of nephrotoxicity in 
particular. 
 
RECOGNITION AND EARLY INTERVENTION 
 
Most episodes of drug-induced renal impairment are reversible. Renal function 
generally returns to baseline provided the impairment is recognized early and the 
offending medication is discontinued.52 Failure to act on available information 
relating to clinical findings or laboratory results was the most common monitoring 
error, occurring in 37 percent of preventable adverse drug events, including those 
affecting the kidney, in older ambulatory patients.48A decrease in renal function as 
evidenced by a rise in serum creatinine levels following the initiation of a drug signals 
the possibility of drug-induced renal injury. An exception to this is an increase in 
serum creatinine following the initiation of cimetidine (Tagamet) or tri-methoprim 
(Proloprim), because they compete with creatinine for tubular secretion and are not 
associated with kidney damage or urine abnormalities.52 Although there are no 
standard guidelines used to interpret changes in serum creatinine, a 50 percent rise 
from baseline, an increase of 0.5 mg per dL (40 µmol per L) or more when baseline 
serum creatinine is less than 2 mg per dL (180 µmol per L), or an increase of 1 mg per 
dL (90 µmol per L) or more if baseline creatinine is greater than 2 mg per dL have 
been used as biochemical criteria of acute renal failure. At the first sign of renal 
dysfunction, the patient's medication list should be reviewed to identify offending 
agents. If multiple medications are present and the patient is clinically stable, 
physicians should start by discontinuing the drug most recently added to the patient's 
medication regimen. Attention should then be directed at avoiding further renal insults 
by supporting blood pressure, maintaining adequate hydration, and temporarily 
discontinuing all other possible nephrotoxins.  
  
Manage the renal injury as needed by replacing fluid volume, starting dialysis, 
adjusting drug doses, trying steroids in cases of acute interstitial nephritis, and 
avoiding repeated exposure. When in doubt about the cause of renal injury, hold all 
potentially offending drugs. 
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First Line Treatment for drug induced renal injuries 13 
Mechanisms and principles for prevention of drug nephropathy 10 
 
 
  
Mechanisms of renal 
susceptibility 
 
  
  Principles for 
prevention 
          
         Examples 
A Large drug exposure due 
to high renal blood flow 
1. Avoid systemic drug 
administration 
 
2. Limit total drug use 
1.Intraperitoneal 
administration of 
cisplatin for localized 
intraperitoneal tumor. 
 
2.Monitor 
aminoglycoside levels 
to maintain in 
therapeutic range, 
substitute nontoxic 
antibiotic based on 
microbial sensitivities. 
 
B Specialized renal 
hemodynamics regulated 
by vasoactive substances 
Avoid drugs that inhibit 
prostaglandin synthesis 
Substitute 
acetaminophen or 
nonacetylated 
salicylates ans sulindac 
for other NSAIDS 
 
C Tubulaar epithelial cell 
drug accumulation due to 
luminal and 
contraluminal transport 
1. Inhibit drug 
administration from the 
luminal membrane 
 
2.Inhibit drug absorption 
1. Hydration with 
chloride anions during 
cisplatin therapy, 
calcium 
supplementation during 
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 Table 10  
 
  
from the contraluminal 
membrane 
aminoglycoside 
therapy. 
 
2. Cilastatin inhibition 
of imipenem toxicity 
 
D Renal metabolism of 
drugs to toxic species 
Use drugs with nontoxic 
renal metabolites 
Renal metabolism of 
active sulindac to 
inactive sulindac 
sulfoxide 
 
E Cellular dysfunction due 
to drug induced 
increased energy 
requirements 
Decrease cell energy 
needs by reducing cell 
memebrane transport 
activity 
Furosemide use during 
amphotericin therapy 
to reduce ischemia and 
toxicity to the 
medullary thick 
ascending loop of 
henle 
 
F Water reabsorption and 
concentration of toxins 
within the tubular lumen 
promoting increased 
epithelial cell membrane 
contact and transport into 
cells  
1. Prevent 
dehydration 
 
2. Use of osmotic 
diuresis to increase 
luminal water 
concentration and 
tubular flow rate. 
1. NaCl  repletion 
to prevent 
amphotericin 
toxicity. 
 
2. Possible 
reduction of 
contrast 
nephropathy by 
mannitol 
diuresis. 
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LITERATURE REVIEW 
 
• Marie-Laure Cittanova, Anne Zubicki et al.,14 conducted a prospective 
study that included 249 patients admitted for aortic surgery with ACEI’s. 
Preoperative & post operative glomerular filtration rates were assessed with 
pre-operative & post operative creatinine clearance measurements. 
Postoperative renal impairment was defined as a 20% decrease in GFR 
between day 0 (before surgery) and day 7+-1 day (after surgery).Chronic 
preoperative ACEI’s treatment is significantly associated with postoperative 
renal impairment. Inhibition of compensatory mechanisms caused by rennin 
angiotensin system blockade might be responsible for the observed decrease in 
renal function in patients chronically treated with ACEI’s undergoin aortic 
surgery.         
     
• Gary.C.Curhan, Eric.L.Knight et al.,15 studied on 1697 women 
participating in the nurses health study about the lifetime use of 
acetaminophen, aspirin & NSAIDS. The main outcome was change in 
estimated glomerular filtration rate in 11 years. The mean +- SD estimated 
GFR decreased from 88+-17 to 79+-17ml/min per 1.73m2. Acetaminophen use 
was associated with an increased risk of a GFR decline of atleast 30ml/min per 
1.73m2 & a GFR decline of 30% or greater. Hence high acetaminophen use 
may increase the risk of loss of renal function.    
     
• Thomas.V.Perneger, Paul.K.Whelton & Michael.J.Klag.,16  studied that 
people who take analgesic drugs frequently may be at increased risk of 
ESRD.They studied on 716 pt’s treated for ESRD & 361 control subjects. 
Participants were interviewed about their past use of medications containing 
acetaminophen ,aspirin, NSAIDS. Heavier acetaminophen use was associated 
with an increased risk of ESRD in a dose-dependent fashion. Approximately 8 
to 10 percent of the overall incidence  of ESRD was attributable to 
acetaminophen use.     .     
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• Perneger et al.,17 reported the results of a case-control of the use of over-the 
counter  analgesic drugs as a risk for ESRD. Heavy average use of 
acetaminophen intake (more than 1 pill per day) and medium-to-high 
cumulative acetaminophen intake (more than 1000 pills in a lifetime) each 
doubled the odds of ESRD. The results also suggested an association between 
ESRD & high lifetime intake (5000 or more pills) of NSAIDS other aspirin.
          
• Hemsreet B.A.,18  documented the association of various antimicrobial 
medications with the development of RTA. Anti microbial- associated RTA is 
a relatively uncommon adverse effect, with most reports involving 
amphotericin B, trimethoprim/ sulfamethoxazole & outdated tetracycline. 
These agents may induce RTA either through direct tubular toxicity or as 
fuction of their pharmacologic action.     
         
• Aranyl , Safirstein RL.,19 Reported on cisplatin nephrotoxicity. The kidney 
accumulates cisplatin to a higher degree than other organs perhaps via 
mediated transport. Functionally, reduced renal perfusion & a concentrating 
defect characterize its nephrotoxicity, whereas morphologically necrosis of the 
terminal portion of the proximal tubule and apoptosis predominantly in the 
distal nephron characterize its effect on cellfate. Metabolic responses, cell 
cycle events and the inflammatory cascade seem to be important determinants 
of the degree of renal failure induced by cisplatin.    
           
• Cheng HF, Harris RC.,20 reported on renal effect of NSAIDS and selective 
cyclo-oxygenase-2-inhibitors. Similar to conventional NSAIDS, inhibition of 
cox-2 may cause edema and modest elevations in blood pressure in a minority 
of subjects. Cox-2 inhibitors may also exacerbate pre-existing hypertension 
(or) interfere with otyer anti-hypertensive drugs. Occassional acute renal 
failure has also been reported.      
       
• Roling J, Schmid H, et al.,21 Studied on HIV- associated renal diseases and 
highly active ART_ induced nephropathy. HIV- related renal impairment can 
present as acute (or) chronic kidney disease- leads to changes in renal function 
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by inducing metabolic vasculopathy and renal damage. Chronic renal disease 
can be caused by multiple pathophysiological mechanisms leading to HIV 
associated nephropathy.  
 
•  Quershi Iz. et al.,22 investigated the effects of ACEI’s on recombinant human 
erythropoietin in CRF patients. The study was conducted in 100 patients (55 
males, 45 females) divided into 2 groups. Group 1 patients received rHuEPo 
and ACI’s while group 2 received rHuEPo with other anti-hypertensives. 
Datas showed that ACI’s interfered with rHuEPo therapy for treatment of 
anaemia in CRF.         
 
• Weisbord SD et al.,23  Studied that the intravascular administration of 
iodinated radio-contrast media can lead to acute renal dysfunction. Risk 
factors include pre-existent kidney disease, diabetic mellitus, dose of radio-
contrast used, advanced congestive heart failure and intravascular volume 
depletion.  
 
• Aleksa.K, et al.,24  Studied on ifosfamide induced nephrotoxicity in children 
with cancer. Nephrotoxicity induced by ifosfamide with younger children less 
than 3 years is more vilnerable. The underlying hypothesis is that renal 
ontogeny is involved in the expression and activity of the cytochrome P450 
enzymes responsible for metabolism to the nephrotoxic chloroacetaldehyde.
       
•  Zimmermann AE, et al.,25 diagnosed tenofovir-associated acute and chronic 
renal disease in patients with HIV infection.They studied tenofovir associated 
therapy had classic findings of acute tubular necrosis, compared the findings 
with 22 patients. The mean serum creatinine levelincreased from 0.9 to 3.9 
mg/dl, and decreased to 1.2 mg/dl during recovery. Tenofovir-associated ARF 
manifests as acute tubular necrosis thay may not resolve with tenofovir 
withdrawal. It is associated with multiple drug interactions leading to an 
increased risk ofARF. 
 
Department of Pharmacy Practice, K.M.C.P, Madurai  Page 52 
 
• Goldman RD, Koren G26 studied Amphotericin B nephrotoxicity in children. 
Neprotoxicity includes decreased glomerular filtration rate and distal 
tubulopathy with urinary loss of potassium and magnesium, renal tubular 
acidosis, loss of urine concentrating ability, and sometimes fanconi’s 
syndrome.   
 
• Dovas.S, et al.,27 reported 2 cases that have implicated aminoglycoside- 
impregnated cement in acute renal failure after surgery for an infected total 
knee arthroplasty. 2 more cases of post operative ARF after use of combined 
tobramycin- plus vancomycin impregnated cement in total hip arthroplasty 
have also been reported.        
 
• Widemann BC,et al.,28  estimated the current incidence of high dose 
methotruxate (HDMTX) induced renal dysfunction in patients with 
osteosarcoma and compared the efficacy and recovery of renal function for 
dialysis – based methods of MTX removal with treatment using CPDG2 
(carboxypeptidase G2). Approximately 1.8% of patients with osteosarcoma 
(68 of 3887 patients) who received HDMTX developed nephrotoxicity.  
 
• Fred G. Silva.,29 studied that renal changes induced by chemicals can effect 
the tubules, interstitium or both. This review of chemical induced nephropathy 
in human considers acute tubular necrosis, interstitial nephritis and tubulo 
interstitial nephritis or nephropathy because the tubules and interstitium are so 
intimately related injury to one of these 2 components may eventually lead to 
injury of the other , resulting in tubulo interstitial disease.    
 
• Busauschina A, et al.,30 discussed on cyclosporine neprotoxicity- primary 
immunosupresant for the prevention of allograft rejection in solid organ 
transplantation. The underlying pathomechanisms of this toxicity reflect an 
altered release of vasoactive substances such as angiotensin2, endothelin, 
prostaglandins and nitric oxide as well as the stimulation of proliferative genes 
such as transforming growth factor- beta, osteopontin and collagen1 & 1V. 
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• Kintzel, Polly E.,31 discussed on anticancer drug induced kidney disorders, its 
incidence, prevention and management. Toxicity can be catagorised as pre-
renal uraemia, intrinsic damage or post –renal uraemia. Mechanisms of 
chemotherapy induced renal dysfunction generally include damage to 
vasculature or structures of the kidney,haemolytic uraemic syndrome and pre 
renal perfusion deficits. Dose related nephrotoxicity subsequent to 
administration of certain chloroethlylnitrosourea compounds is commonly 
heralded by increased serum creatinine levels, uraemia and protienuria. 
Cisplatin and carboplatin cause dose related renal dysfunction. High dose 
azacitidine causes renal dysfunction manifested by tubular acidosis, polyuria 
and increased urinary excretion of electrolytes, glucose and aminoacids. 
Haemolytic uraemia is a rare adverse effect of gemicitabine. Methotruxate can 
cause increased serum creatinie levels, uraemia and haematuria.  
 
• Ahmad, Syed R, et al.,32 conducted a study in order to understand the 
association between acute renal failure and the two cox-2 inhibitors-celecoxib 
and rofecoxib. The literature search identified 19 cases of acute renal 
impairment in association with celecoxib and rofecoxib. Data from AERS 
(Adverse Event Reporting System) and published case reports suggest that use 
of both these drugs is associated with renal effects similar to that of 
conventional non-selective NSAIDS. Patients at greatest risk for renal injury 
are those with pre-existing renal impairment, heart failure, liver dysfunction 
those taking diuretics or ACIs and the elderly. 
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AIM AND OBJECTIVE OF THE STUDY 
 
Drug toxicity in hospitalized patients is a frequent adverse event with 
nephrotoxicity accounting for nearly 20% of all drug toxicity. Hospitalized patients 
are vulnerable to renal failure from a variety of causes, including diagnostic 
procedures (1V contrast), sudden decrease in blood pressure (gastrointestinal bleed, 
sepsis, variceal bleed) and the addition of nephrotoxic medications (aminoglycosides, 
amphotericin, chemotherapy). Upto 16% of patients with baseline normal renal 
function who experience renal injury within the hospital setting have medication-
induced renal failure. 
 
   The present study has made an attempt to reveal the following details:- 
 
• To study on various renal diseases reported in the nephrology department of the 
hospital. 
• Study on patients with drug induced renal diseases. 
• Etiology of drug induced renal diseases. 
• Study on corresponding elevations in laboratory parameters in drug induced renal 
diseased patients. 
• Clinical management of patients with drug induced renal disease. 
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PLAN OF THE WORK 
 
The present dissertation was undertaken to study the incidence of drug 
induced renal disease and its clinical management. 
 
• Collection of patients admitted with drug induced renal disease in the nephrology 
unit of the hospital. 
• Collection of case history to point out the etiology of drug induced renal disease 
• Corresponding elevations in the clinical parameters are observed. 
• Clinical management of drug induced renal disease undertaken is studied. 
• Consultation with the Nephrologist 
• Submission of reports obtained. 
 
BACKGROUND OF THE STUDY 
 This prospective study was conducted at Nephrology department in 
“MEENAKSHI MISSION HOSPITAL AND RESEARCH CENTRE” MMHRC) 
MMHRC: This hospital was located in lake area at Madurai. This is a 750 plus 
bedded hospital built in late 20th century by Dr. SETHURAMAN (FOUNDER). The 
hospital was especially built for lower realms of humanity in our country and  it 
provides  multispecialty medical and surgical treatment at very high levels. The 
quality control service for each department has been done and their presentation also 
has been done in every year. This hospital is a deemed autonomous teaching hospital 
which have academic programs for paramedical disciplines. 
  This study was conducted between DECEMBER 2012 – JULY 2013. 
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OBSERVATION AND RESULTS 
 
1.  AGE DISTRIBUTION 
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2. SEX DISTRIBUTION 
 
538 patients were admitted in the nephrology department of MMHRC due to 
various types of renal diseases during the period of Dec 2012– Jul 2013. The sex 
distributions of the patients with renal diseases studied were 366 (72%) males and 172 
(28%) females. 
 
               
                                           
 
 
 
 
  
MALE, 366
FEMALE, 172
CONTRIBUTING POPULATION
MALE 
FEMALE
68% 
32% 
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3. TYPE OF RENAL DISEASES DISTRIBUTED AMONG THE PATIENTS. 
 
 
TYPE OF RENAL DISEASES 
 
NO. OF PATIENT (%) 
 
CHRONIC KIDNEY DISEASE 
 
 
END STAGE RENAL DISEASE 
 
 
CHRONIC ALLOGRAFT 
 NEPHROPATHY 
 
ACUTE RENAL FAILURE 
 
 
SYSTEMIC LUPUS ERYTHEMATOUS 
 
 
NEPHROLITHIASIS 
 
 
CHRONIC OBSTRUCTIVE UROPATHY 
 
 
NEPHROTIC SYNDROME 
 
 
DRUG – INDUCED KIDNEY DISEASES 
 
 
OTHERS 
 
190 (35.31%) 
 
 
142 (26.39%) 
 
 
26 (4.83%) 
 
 
58 (10.78%) 
 
 
12 (2.23%) 
 
 
6 (1.12%) 
 
 
12 (2.23%) 
 
 
24 (4.46%) 
 
 
30 (5.57%) 
 
 
38 (7.06%) 
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ESRD   – END STAGE RENAL DISEASE 
CKD   – CHRONIC KIDNEY DISEASE 
CAN   – CHRONIC ALLOGRAFT NEPHROPATHY 
ARF   – ACUTE RENAL FAILURE 
SLE   – SYSTEMIC LUPUS ERYTHEMATOUS 
NL   – NEPHROLITHIAIS 
COU   – CHRONIC OBSTRUCTIVE UROPATHY 
NS   – NEPHROTIC SYNDROME 
DI   – DRUG INDUCED KIDNEY DISEASE 
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4.  AGE DISTRIBUTION 
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DISTRIBUTION OF DRUG INDUCED RENAL DISEASES
 
The Study included 30 patients with Drug Induced Renal Diseases from the 
Nephrology Unit. Among these 30 patients 24 males (80%)  and
were identified. 
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FEMALES
 
5.  SEX DISTRIBUTION 
 6 females (20%) 
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6. CLASSIFICATION OF RENAL DISEASE
 
The patients were characterized according to the classification of Drug 
Induced Renal disease.    
 Most of the medications have caused direct injury to the kidney. 
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7. TYPE OF DRUG INDUCED RENAL DISEASE DISTRIBUTED AMONG 
PATIENTS. 
 
Patients were characterized according to the type of Drug induced renal disease. 
 
 
 
NAME OF THE DISEASE 
 
MALES 
 
FEMALES 
 
TOTAL 
 
ACUTE INTERSTITIAL 
NEPHRITIS 
 
CHRONIC KIDNEY DISEASE 
 
 
CYCLOSPORINE TOXICITY 
 
 
DRUG INDUCED AZOTEMIA 
 
 
 
DRUG INDUCED PRE RENAL 
INJURY 
 
 
8 
 
 
4 
 
 
2 
 
 
4 
 
 
 
4 
 
2 
 
 
2 
 
 
0 
 
 
0 
 
 
 
4 
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6 
 
 
2 
 
 
4 
 
 
 
8 
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8. CONDITIONS ASSOCIATED WITH RENAL INSUFFICIENCY 
 
  The various conditions associated with renal injury were analyzed among the 
patients as follows:-  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NAME OF DISEASE NUMBER  OF PATIENT 
 
DIABETES MELLITUS 
 
HYPERTENSION 
 
VOLUME DEPLETION 
 
DYSURIA 
 
ANAEMIA 
 
HAEMATURIA 
 
 
9 
 
7 
 
3 
 
4 
 
5 
 
2 
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9.   DRUGS THAT INDUCES RENAL DISEASES 
 
            Drugs / toxins responsible for nephrotoxicity were analyzed among the 
patients as follows:-  
 
 
 
 
 
 
 
 
 
Class of Drug 
 
 
No. of patient 
 
NSAIDs 
 
LASIX / MANNITOL 
 
ANTIBIOTICS 
 
  CYCLOSPORINE 
 
RADIO – CONTRAST DYE 
 
ACEI’s 
 
RIFAMPICIN 
 
12 
 
5 
 
2 
 
2 
 
3 
 
3 
 
3 
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10. ELEVATIONS IN CLINICAL PARAMETERS STUDIED INCLUDES:- 
               By monitoring the patient’s laboratory data, it is possible to detect a drug – 
related decline in renal function. The laboratory data that provide information about 
the functional capacity of the kidneys include the SERUM UREA and SERUM 
CREATININE concentration. 
 
Normal values:-  
Serum urea: - 20 – 40 mg / dl                        
Serum Creatinine: - 0.5 – 1.5 mg / dl 
 
S.NO 
 
 
ABNORMAL VALUE(in 
mg/dl) 
 
CORRECTED VALUE(in mg/dl) 
SERUM 
UREA 
SERUM 
CREATINE 
SERUM 
UREA 
SERUM 
CREATININE 
1 41 2.4 15 0.4 
2 72 1.8 54 1.5 
3 50 3.3 45 2.5 
4 65 5.4 55 2.3 
5 120 1.6 78 1 
6 72 1.2 50 0.8 
7 72 2.5 15 0.7 
8 140 2.9 95 1.5 
9 116 5.4 95 6.5 
10 63 1.9 52 1.2 
11 91 1.3 52 0.8 
12 77 1 37 1 
13 47 2 28 1.8 
14 191 8.5 120 6.2 
15 176 7.8 104 6.8 
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 SERIAL 
NO. 
 
 
ABNORMAL VALUE(in 
mg/dl) 
 
CORRECTED VALUE(in mg/dl) 
SERUM 
 UREA 
SERUM 
CREATINE 
SERUM 
 UREA 
SERUM 
 CREATININE 
16 67 4.5 20 0.9 
17 54 3.6 42 1.8 
18 68 5.3 35 1.3 
19 56 2.4 45 1.2 
20 94 3.6 38 2 
21 72 2.2 39 0.8 
22 86 2.5 15 0.7 
23 140 2.9 39 1.6 
24 161 3.4 31 2.6 
25 70 1.9 98 5.6 
26 93 1.3 52 0.8 
27 78 1.3 37 1.7 
28 49 2 28 1.8 
29 187 8.5 120 8.2 
30 57 1.8 55 1.4 
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11.  TREATMENT MODALITIES 
  
Distribution of therapeutic modalities among the patients :- 
 
 
CONVENTIONAL  
 
DIALYSIS 
 
25 (87%) 
 
5 (13%) 
 
 
 
 
 
 
 
 
 
  
87%
13%
TREATMENT MODALITIES
CONVENTIONAL DIALYSIS
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DISCUSSION AND CONCLUSION 
 
In this prospective study 538 patients were having various kidney diseases. 
Prevalence of kidney disease is very high between age group 51to 60 and 41 to 50 
were 160 and 146 respectively, and it is due to metabolic rate, food habits, 
environment etc… 
 
Sex distribution among the sample population 
It was observed that male (68%) predominance exists in this study compared 
to females (32%).  
 
Drug induced renal disease:-  
Drug induced renal disease has occurred in 5.57% of the hospitalized patients 
coming with various renal diseases during the study period. In this study, 30 patients 
with drug induced nephrotoxicity have been observed out of this noted 20% female 
(6) and 80% male (24) patients, it is mainly due to sedentary life style. 
 
Out of these 30subjcts 22 subjects having  intra renal disease,8 subject having  
pre  renal disease due to insufficient in take of  water, quality of water, calcium  rich 
diet like cow milk, dry fish, variety of pickles etc.. 
Population having metabolic disorder like Diabetes mellitus and hypertension  were 
more prone to get drug  induced kidney disease because of food habits and  life style. 
 
Age distribution  
In this study, patients with an age group between 10 – 80 were exposed to 
drug induced renal disease.  
 
This study showed that most of the patients with an age group between 51 to 
70 were more prone to develop drug induced renal disease. In age group between 
51to60, 8 patients were developed drug induced renal injury. Among  these  8 
patients,2 patient- a  case  of   road traffic accident – on treatment with diuretics 
developed  toxicity, another 1 patient developed antibiotic induced renal injury and 
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other r 4 patient developed with intake of NSAIDS for complaints of back pain, and 1 
patient developed rena ltoxiicity due radiocontrast dye.  
 
8 patients of an age group between 61 – 70 developed drug induced renal 
toxicity.  Among  these 8, 2 patient developed  radio contrast dye toxicity on post 
coronary angiogram, 3 patients developed diuretic induced  renal injury and  3 patient 
developed  anti hypertensive  induced toxicity. 
 
6 patients of an age group between 41 – 50 developed drug induced renal 
toxicity.Among these 6, 4   patients developed NSAID induced renal toxicity, and  1  
patient developed renal toxiccity with antibiotic. 
 
4 patients of an age group between 71 – 80 developed drugs induced renal 
toxicity. All 4 patients with NSAID. 
 
2 patients with an age group between 11 – 20 developed drug induced renal 
disease.1patient on treatment with Rifamycin toxicity and another one patient 
developed cyclosporin induced renal toxicity. 2 patients of an age group between 31 – 
40 developed drug induced renal disease, due to Rifamycin induced toxicity for 
complaints of tuberculosis. 
  
Drugs that induces nephrotoxicity  
 
On conducting this study, it was possible to find out that a wide variety of 
drugs induced nephrotoxicity in patients who were hospitalized. 
 
It was observed that 6 patients were admitted for Non- steroidal Anti-
inflammatory Drug (NSAID) induced renal injury and 3 patients with lasix (or) 
mannitol induced renal injury. 
 
Similarly other drugs such as cyclosporine, radio- contrast dye,  antibiotics 
[ciprofloxacin, levofloxacin], Angiotensin Converting Enzyme inhibitors (ACEI) and  
rifampicin  induced renal injury was also observed in patients. 
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NSAIDS (Non Steroidal Anti- inflammatory Drugs) inhibit the formation of 
prostaglandins through the inhibition of cyclo- oxygenase enzymes, thus reduces the 
overall blood flow to the kidneyand induces renal injury.Long term use of NSAIDs 
can cause chronic renal insufficiency. Patients at risk for kidney damage with 
NSAIDS include those with decreased effective arterial blood volume. It was found 
that 6 patients tooh treatment for NSAID induced renal injury. 
 
Diuretics stimulate renal vasoconstriction with marked uptake of sodium 
chloride and thus decreases urine output. Prolonged vasoconstriction can lead to 
tubular dysfunction and tubular necrosis. It is frequently associated with pre- renal 
azotemia. It was observed that 3 patients were treated for diuretic induced renal 
injury. 
 
Antibiotics cause intra-renal injury such as Acute Interstitial Nephritis – a 
hypersensitivity or allergic reaction to the drug. 2 patients were found with antibiotic 
induced renal injury. 
 
Radio- contrast dye induces acute vasoconstriction, increases medullary 
oxygen consumption and eventually leads to tubular ischemia. Severe toxicity is more 
frequent in diabetic patients with pre- existent renal insufficiency. Prevention can be 
aimed by vigorous hydration using low doses of contrast media and avoiding multiple 
contrast procedures. 1 patient was exposed to radio- contrast dye induced renal injury. 
 
Cyclosporine induces vasoconstriction of afferent and efferent arteriole, 
leading to a drop in Glomerular Filtration Rate. Cyclosporine is dose- dependent and 
so the dose should be monitored to avoid larger drop in Glomerular Filtration Rate. 1 
patient was exposed to cyclosporine toxicity. 
 
Patients whose renal function depends on angiotensin 2 for maximum renal 
function, may experience a decline in function with the addition of Angiotensin 
Converting Enzyme Inhibitors. ACEI’s reduces the renal blood flow to the kidney and 
induces injury. 1 patient was treated for ACEI induced renal injury. 
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Conditions associated with renal insufficiency 
 
On analyzing the laboratory parameters, it was observed that conditions such 
as diabetes, hypertension, dysuria, anaemia and haematuria were associated with renal 
insufficiency in patients admitted with drug induced renal disease. Diabetes was 
observed in majority of the patients. 
 
Drug induced intra – renal injury (directly causing injury to the tubular, 
vascular, glomerular and interstitial tissues) is predominantly observed rather 
than pre- renal injury (causing decreased blood flow to the kidneys). On 
analyzing the type of drug induced renal disease, Acute Interstitial Nephritis was 
found to be pre- dominant. 
 
Treatment Modalities 
The treatment involves conventional (or) dialysis. 
The basic principle for prevention of drug induced renal disease is to avoid the 
use of potentially nephrotoxic drugs. 
 
Conventional treatment involves:-  
 Withdrawing the nephrotoxic drug 
 Correcting the dose 
 Following the trough levels 
 Hydrating using saline infusion. 
 
These approaches are made to provide careful and adequate hydration to 
establish high renal tubular flow rate and to maximize the efficacy of drug with 
minimum toxicity.  
Hemodialysis is usually carried out for 4 – 6 hours 3 times weekly in acute 
renal injury. Most patients notice a gradual reduction of their uraemic symptoms 
during first 6 weeks of treatment. 
 
Preventive measures such as using alternative non- nephrotoxic drugs, 
correcting the risk factors, assessing the baseline renal function before initiation of 
therapy, correcting the dose, monitoring renal function and vital signs during therapy, 
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avoiding nephrotoxic drug combinations should be undertaken in order to prevent 
further injury to the kidney. Adequate hydration is important to maintain renal 
perfusion and to avoid drug induced renal impairment.  
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